- Relapsed and refractory B-cell CD-22 positive malignancies
- Available as 10 mg/mL clear and colourless liquid ( 17.5 mL / vial)
- Preservative-free - vials should be used only once.
- Refrigerate vials.
- Do NOT shake vial or solution.
- Further diluted solution in NS stable 24 hours at room temperature
-Solution Compatible: NS only
Incompatible: Dextrose solutions, DO NOT mix with any other drugs or IV solutions
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
|IV Intermittent Infusion||
YES Slow infusion through a 0.22 micron in-line filter
Usual dilution: Dilute to a final concentration of 1 mg/mL
· Start initial infusion at 0.5 mg/kg/hr (max 50 mg/hr) for first hour. If no hypersensitivity or infusion-related events occur, increase rate in increments of 0.5 mg/kg/hr (max 50 mg/hr), every 30 min to a maximum of 400 mg/hr. If reaction occurs, stop infusion temporarily and notify physician. Once patient improves and tumor lysis syndrome and pulmonary infiltrate have been ruled out, re-start at 50% of rate at which reaction occurred and increase rate as directed above as tolerated.
|IV Continuous Infusion||NO|
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- 360 mg/m2 IV weekly x 4 week
- 120-1000mg/m2 weekly x 4 weeks
- Occasional: Infusion reaction (usually associated with first infusion), nausea/vomiting, diarrhea, chills/rigors, back pain, fever, fatigue, headache, dizziness, flu-like symptoms, infection, anxiety, thrombocytopenia (delayed)
- Rare: Severe allergic reaction, bronchospasm, tachycardia, tachypnea, hypotension, hypertension, flushing, chest pain and abdominal pain
**For any infusion toxicities,refer to protocol for detailed information on management**
- Pre-medicate with acetaminophen and diphenhydramine
- Anaphylactic precautions at bedside
- Ensure no antihypertensive medication has been taken within 12 hours of beginning the infusion as hypotension may occur
- Monitor vital signs, including BP: immediately prior to infusion, Q 15 minutes during first hour, Q 30 minutes during second hour and hourly during third hour and until completion of the infusion. Also monitor 30 and 60 minutes post infusion.